Fractyl Health (NASDAQ:GUTS) Receives “Buy” Rating from HC Wainwright

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $8.00 price objective on the stock.

Several other research firms have also commented on GUTS. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Fractyl Health has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Stock Performance

GUTS stock traded up $0.02 during midday trading on Thursday, hitting $0.78. 774,106 shares of the stock traded hands, compared to its average volume of 4,084,680. The firm has a market cap of $124.22 million, a P/E ratio of -0.61 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The stock’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $1.10. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.23. On average, analysts expect that Fractyl Health will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pale Fire Capital SE lifted its holdings in Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares in the last quarter. Accredited Investors Inc. purchased a new position in shares of Fractyl Health in the first quarter worth about $46,000. Virtu Financial LLC purchased a new position in shares of Fractyl Health in the fourth quarter worth about $153,000. Susquehanna Portfolio Strategies LLC purchased a new position in shares of Fractyl Health in the fourth quarter worth about $108,000. Finally, Quadrature Capital Ltd lifted its stake in shares of Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock worth $640,000 after buying an additional 277,174 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.